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Type 1 diabetes mellitusAims:Wehypothesized that adults with type 1 diabetes and severe polyneuropathy have alterations in neuronal
transmission at different anatomical levels. The aimswere to investigate upstreamsensory neuronal activation in
terms of peripheral, spinal, precortical, and cortical transmission.
Methods: 48 participants with type-1 diabetes and polyneuropathy, and 21 age-matched healthy participants
were included. Electrophysiological median nerve recordings were used to analyze peripheral transmission at
Erb's point (P9-N11); spinal evoked potentials at Cv7 (P11-N14); subcortical evoked potentials at Oz (N14-
P18); early cortical evoked potentials at CP5 (N20-P22); late cortical evoked potentials at C1 (N60-P80) and es-
timated cortical inter-peak latencies as measures of central conduction time.
Results: In comparison to healthy, the presence of diabetes prolonged peripheral transmission at P9 and
N11 (+0.49 ms, p = .000; +0.47 ms, p = .04, respectively), early cortical evoked potentials at CP5: N20
(+2.41 ms, p = .003) and P22 (+5.88 ms, p = .001) and cortical potentials at C1: N60 (+39.08 ms, p = .001)
and P80 (+54.55 ms, p = .000) and central conduction time.
Decreased amplitudes were shown peripherally (−2.13 μV, p = .000), spinally (−0.57 μV, p = .005) and pre-
cortically (−0.22 μV, p = .004).
In both healthy and people with diabetes increased central conduction time were associated with decreased
parasympathetic tone (ρ = −0.52, p = .027; ρ = −0.35, p = .047, respectively).
Conclusion: Neuronal afferent transmission and brain responses were significantly impaired in diabetes and the
presence of prolonged central conduction time is indicative of severe extensive neuronal damage.
Trial registry number: EUDRA CT: 2013-004375-12; clinicaltrials.gov: NCT02138045.
© 2020 The Author(s). This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
An increasing number of people is diagnosed with diabetes mellitus
and since treatment has improved, people have longer life-expectancy.
Consequently, the presence of diabetes induced macro- and microvas-
cular complications are increasing globally, plausibly due to longer dis-
ease duration. Among the microvascular complication, polyneuropathyrsity Hospital, Medicinerhuset,
article under the CC BY-NC-ND licens
ous User (n/a) at Aalborg Hospital f
y. No other uses without permissionwill affect up to 50% of adults with long-term type 1 diabetes. The path-
ogenesis ismultifactorial and complex and includes vascular, metabolic,
immunemediated and inflammatory pathways.1,2 The clinical manifes-
tations of diabetic symmetrical polyneuropathies (DSPN) include sen-
sory and motor loss of the peripheral nerves to feet and hands,
causingpainful or painless sensorydisturbances.3 Classically these alter-
ations are measured by nerve conduction studies, which confirm large
fiber axonopathy. Autonomic nerves to viscera may also affected,4–6
and e.g. decreased parasympathetic tone to the heart may lead to ar-
rhythmias and sudden death.7 In the central nervous system (CNS), al-
terations of brain responses occur at multiple levels and include
transmission alterations in the spinal cord, brainstem and higher corti-
cal structures. Structural changes in the CNS can objectively be assessede (http://creativecommons.org/licenses/by-nc-nd/4.0/).
rom ClinicalKey.com by Elsevier on September 09, 2020.
. Copyright ©2020. Elsevier Inc. All rights reserved.
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white matter volume, structural changes within nerve tracts and
changes in metabolic function.
The use of EEG and somatosensory evoked potentials (SEPs) are ad-
vanced methods to evaluate brain responses and the brain integrity
from peripheral stimulations.4,8,9 Compared to MRI, EEG has a better
temporal resolution, making it possible to investigate the stimulus spe-
cific exogenous response of the ascending sensory pathways.8 Further-
more, resting state EEG studies have supported diabetes induced
neuronal changes in the brain and the brain's sensory processing
capabilities.10 These changes can be interpreted as the net result of
many synchronous distorted neuronal processes including transduc-
tion, transmission, interneuronal communication, and perception. Me-
dian nerve stimulation is a reliable method for eliciting SEP's and the
upstream action potentials can be followed from the periphery to the
spinal cord, to the brainstem and finally to the cortex.11 The compre-
hensive technique provides detailed information on the diabetes in-
duced neuronal alterations on the different level of the nervous
system, which is important in understanding the pathogenesis of dia-
betic neuropathies.
Previous pioneering studies have thoroughly investigated SEP's in
type 1 diabetes to characterize the somatosensory pathway from the
periphery to the CNS in diabetes.9,12 The studies concluded that the de-
gree of dysfunction in the somatosensory afferent pathway depends on
the stage of peripheral neuropathy and can be characterized mainly by
alteration of the cortical sensory complex (reduced amplitude) and pe-
ripheral transmission delay. However, due to different patient cohorts,
previous hyperglycemic treatment regiments and neurophysiological
methods, the existing electrophysiological studies have shown contra-
dictory results in characterizing the central conduction time assessed
as interpeak latencies of SEP's.9,12,13 Therefore, we aimed to provide a
contemporary characteristic of the afferent neuronal transmission (pe-
riphery to cortex) and central conduction in people with long-term
type 1 and severe polyneuropathy.
We hypothesize that adults with type 1 diabetes and verified DSPN
have extensive alterations of neuronal transmission evident at multiple
anatomical levels in comparison to age-matched healthy participants.
The aim of the current studywas to compare the upstream sensory neu-
ronal transmission in type 1 diabetes with DSPN and healthy partici-
pants, and specifically measure latencies and amplitudes to median
nerve stimulations 1) in the peripheral Erb's point, 2) at the Cv7
reflecting the spinal evoked potential, 3) at Oz representing the up-
stream precortical response and 4) at CP5 and C1 representing cortical
processing. Finally, 5) the associations between central conduction
time and 1) disease duration, age and height, 2) median nerve conduc-
tion velocity, median nerve action potential and, 3) parasympathetic
tonewere investigated to studywhethermeasures of axonopathy or au-
tonomic involvement is associated to prolonged CNS transmission.
2. Subjects, materials and methods
2.1. Study population
Forty-eight people with type 1 diabetes were recruited at the
Department of Endocrinology, Aalborg University Hospital, Denmark.
Potential eligible participants were pre-screened based on a recorded
vibration perception thresholds above 18 V. DSPN was verified by
nerve conduction tests, according to the Toronto criteria.2 Additional in-
clusion criteria were age above 18 years, a verified diagnosis of type 1
diabetes for a minimum of 2 years: HbA1c level N 48 mmol/mol
[≥6.5%], stable medication, body mass index N22, and written consent.
Exclusion criteria included type 2 diabetes mellitus, other neurological
disorders than DSPN, estimated glomerular filtration rate b 60 ml/-
min/1.73 m2, calcitonin N25 ng/l, HbA1c level b 48 mmol/mol (b6.5%),
use of glucagon-like peptide-1 receptor agonists or dipeptidyl
peptidase-4 inhibitors. Twenty-one healthy participants were recruitedDownloaded for Anonymous User (n/a) at Aalborg Hospital 
For personal use only. No other uses without permissioamong volunteers fromNorth Jutland andwere age-matched to the pa-
tient group. Inclusion criteria were age above 18 years, normal periph-
eral nerve conduction testing. Exclusion criteria included type 1 and
type 2 diabetes mellitus, neurological disorders and medication that
could alter neuronal function.
Ethical approval was granted by Region Nordjylland, Denmark
(N-20130077, N-20090008) and all participants gave written informed
consent prior to entry. The study was registered in public databases
(EUDRA CT (ref 2013-004375-12) and clinicaltrials.gov (ref
NCT02138045)) and performed in accordance with International Coun-
cil for Harmonization Good Clinical Practice and the Declaration of Hel-
sinki. The experiment was conducted between June 2014 and January
2018 at Aalborg University Hospital.
2.2. Systemic biochemistry
Routine clinical chemistry (HbA1c, cholesterol, and triglycerides)
were analyzed at the Department of Clinical Biochemistry, Aalborg Uni-
versity Hospital.
2.3. Peripheral neuronal assessment – peripheral nerve function
All participants underwent a standardized neurophysiological ex-
amination of the sensory and motor component of the median, ulnar,
sural, radial, tibial, and peroneal nerves, and results were evaluated by
a specialist neurophysiologist. In order to avoid the influence of skin
temperature on conduction velocities, warming measures were used
to ensure that the testing room did not allow skin temperature below
32 °C. For recording of the digital sensory nerve action potentials surface
electrode were used. Electrical stimulation was applied through surface
plastic bar electrodes.
2.4. Autonomic function
Cardiac vagal tonewas recorded in themorning between 09: 00 and
10: 00, with the participant in a comfortable seated position with their
legs supported. The participants refrained fromnicotine and caffeine in-
gestion for 2 h prior to recordings being undertaken. Electrocardio-
graphic electrodes (Ambu Blue Sensor P, Denmark) were positioned
in left and right subclavicular regions and cardiac apex. The ECG
was recorded using a commercially available biosignal acquisition
system (Neuroscope, Medifit Instruments, Essex, UK).14 In brief, the
Neuroscope non-invasivelymeasures brainstem parasympathetic effer-
ent activity, known as cardiac vagal tone, in real time using inbuilt ‘volt-
age controlled oscillators’ which detect phase shifts in the beat-to-beat
RR interval in a process known as ‘phase-shift demodulation’.15 Cardiac
vagal tone is measured on a validated linear vagal scale, where 0 repre-
sents full atropinisation.16 Cardiac vagal tone has been demonstrated
both a sensitive and specific measure of vagal tone in diabetes which
is comparable to other heart rate variability indices.17
2.5. Experimental procedure - somatosensory evoked potentials
Data in this study are the baseline data in a clinical study investi-
gating the neuroprotective properties of liraglutide, in a cohort of
people with type 1 diabetes and confirmed peripheral neuropathy.18
The healthy participants were recruited for a single session as a com-
parative group. In this article, only experimental procedure relevant
to this study will be mentioned. Data presented originate from
peripheral, spinal, and cerebral neurophysiological recordings fol-
lowing electrical stimulation of the right median nerve. For both
groups, the experimental procedure and recording setup are identi-
cal and performed in the same lab. The participants were seated
comfortably in a supine position, with their eyes open during the en-
tire recording. They were instructed to focus on a fixed point on a
wall and try to minimize eye movement during stimulation. Pleasefrom ClinicalKey.com by Elsevier on September 09, 2020.
n. Copyright ©2020. Elsevier Inc. All rights reserved.
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ulation, recording and data analysis.
2.6. Statistical analysis
Descriptive statistics are reported as mean ± standard deviation if
not otherwise stated, and differences were assessed by Students t-test
and Chi-squared tests for categorical variables. To compare latency
for the positive and negative component and peak to peak amplitude
between healthy participants and people with diabetes, analysis was
carried out using one-way multivariate analysis of variance, where
age and height were included as covariates. If significant difference
was seen, post hoc analyses were carried out to elucidate which com-
ponent (positive component, negative component, or peak to peak
amplitude) gave rise to the differences. The model was applied sep-
arately for each of the neurophysiological levels (Erb's point, Cv7, Oz,
CP5, C1 and inter-peak latency). Clinical correlation analyses were
assessed by Spearman's Rho and Bonferroni corrected for multiple
comparisons. p-Values b .05 indicate significant differences. Analysis
was performed using Stata version 14.2 (StataCore LLC, College Sta-
tion Texas, US).
3. Results
All participants concluded the study, detailed demographics are
shown in Table 1.
As expected, people with diabetes had higher heart rate and sys-
tolic blood pressure and accordingly assessment of the parasympa-
thetic tone showed lower cardiac vagal tone reflecting diabetes
induced alterations of the autonomic nervous system. Twenty five
percent had retinopathy which is another sequela of microvascular
complication and none suffered from nephropathy as this was part
of the exclusion criteria.Table 1
Demography and clinical characteristics.
Healthy
Age (range), years 51.3 (40
Gender 6 female
Height, cm 179.8 ±
Weight (range), kg 87.3 (62
Body mass index, kg/m2 26.9 ± 5
Disease duration, (range), years –
Pulse rate, beats/min 66 ± 7
Systolic BP (mmHg) 129 ± 1
Diastolic BP (mmHg) 76 ± 11
CVT 4.33 (1.7
Cholesterol, total, mmol/l 5.40 ± 0
Triglyceride, mmol/l 1.16 ± 0
HDL, mmol/l 1.56 ± 0
LDL, mmol/l 3.30 ± 0
HbA1c, mmol/mol 33.67 ±
HbA1c, % 5.3
Fasting glucose, mmol/l 5.5 ± 0.8
Retinopathy, % of participants 0%
Creatinine, urine 11,019.5
Albumin, urine 0.0083 ±
Median nerve stim. intensity, mA 12.1 ± 5
Median nerve conduction velocity, sensory threshold, m/s 54.7 ± 4
Median nerve amplitude, sensory threshold, mV 26.6 ± 1
Median nerve conduction velocity, motor threshold, m/s 55.4 ± 2
Median nerve amplitude, motor threshold, mV 9.1 ± 1.7
Peroneal nerve conduction velocity, m/s 45.7 ± 2
Peroneal nerve amplitude, mV 3.7 ± 1.5
Sural nerve conduction velocity, m/s 49.7 ± 6
Sural nerve amplitude, mV 6.6 ± 3.2
Data are expressed and mean and SD unless otherwise stated. p-Values b .05 indicate significan
LDL: low-density lipoprotein (LDL).
Downloaded for Anonymous User (n/a) at Aalborg Hospital fro
For personal use only. No other uses without permission. CAssessment of the conduction velocity of the median, sural, and pe-
roneal nerves revealed inter-group differences, confirming DSPN in par-
ticipants with diabetes. The diagnose DSPN was based on clinical
examination and several abnormal neurophysiological measures in
order to rule out e.g. abnormal median nerve conduction caused byme-
chanical obstructions such as e.g. carpal tunnel syndrome. In the same
line, approximately 50% higher stimulus intensity was needed to elicit
a median nerve motor response in diabetes in comparison to healthy
(12.1 mA vs. 18.04 mA).3.1. Evaluation of peripheral, spinal, and cerebral somatosensory evoked
potentials
EEG was successfully recorded in 46 participants with diabetes and
20 participants without diabetes. Due to signal quality all EEG compo-
nent could not always be detected in all recordings. The data analysis
is therefore based on all the detected EEG components. Overall there
were consistent differences between the two groups in SEP's, measured
at multiple anatomical levels (Table 2).
In people with diabetes, post hoc analysis of peripheral transmission
(Erb's point) showed increased latencies at P9 (0.49 ms) and N11
(0.47 ms) as well as decreased peak to peak amplitude (−2.13 μV)
(Fig. 1 and Table 2). Post hoc analysis of the Cv7-spinal SEP's also
showed decreased amplitudes (−0.57 μV). This was again seen at the
Oz pre-cortical level (−0.22 μV).
Post hoc analysis of the early cortical processing assessed at CP5
showed increased latencies in people with diabetes at N20
(2.41 ms) and P22 (5.88 ms), but increased peak to peak amplitude
(2.5 μV). Finally, their late cortical processing also showed increased
latencies of the N60 (39.08 ms) and P80 (54.55 ms), with a decrease
in amplitude (−0.34 μV). Diabetes prolonged the central conduction
time measured between N14 and N60 by 74.4%, from 54.35 ms to
94.77 ms.Type 1 diabetes p-Value
–62) 50.0 (33–71) 0.53
, 15 males 9 female, 39 males 0.48
9.0 178.4 ± 8.6 0.55
–140) 90.0 (63–132) 0.56
.5 28.5 ± 4.9 0.30
32.2 ± 9.5 (14–51)
73.9 ± 10.5 0.001
5 149.9 ± 16 0.007
82.3 ± 10.9 0.33
; 1.89–8.1) 3.0 (1.9; 0.63–6.9) 0.01
.85 4.49 ± 0.80 0.000
.55 1.01 ± 0.64 0.35
.43 1.56 ± 0.54 0.97
.87 2.48 ± 0.56 0.000
3.37 65.96 ± 10.45 0.000
8.1 ± 1
0 12.28 ± 5.36 0.000
25% 0.013
2 ± 7809 10,905.15 ± 5400 0.94
0.006 0.074 ± 0.18 0.10
.65 18.04 ± 6.93 0.001
.5 43.2 ± 7.2 0.000
1.1 13.4 ± 8.0 0.000
.5 49.7 ± 4.9 0.000
8.2 ± 2.2 0.09
.9 37.3 ± 5.4 0.000
1.8 ± 1.3 0.000
.1 42.5 ± 5.8 0.000
3.6 ± 2.3 0.000
t differences. BP: blood pressure; CVT: cardiac vagal tone; HDL: high density lipoprotein;
m ClinicalKey.com by Elsevier on September 09, 2020.
opyright ©2020. Elsevier Inc. All rights reserved.
Table 2
Assessment of evoked potentials at five different points following median nerve stimulation.
Electrode Healthy N Diabetes N Difference p-Value Post-hoc
Erb's point (peripheral processing) 20 44 0.000
P9 latency, ms 9.45 ± 0.39 9.94 ± 0.69 0.49 p = .000
N11 latency, ms 10.98 ± 0.53 11.45 ± 1.10 0.47 p = .044
P2P amplitude, μV 4.40 ± 3.26 2.27 ± 1.81 −2.13 p = .000
Cv7 (spinal processing) 18 30 0.032
P11 latency, ms 11.31 ± 0.68 11.33 ± 1.70 0.02 p = .96
N14 latency, ms 14.34 ± 0.97 13.59 ± 2.19 −0.75 p = .16
P2P amplitude, μV 1.68 ± 0.84 1.11 ± 0.64 −0.57 p = .005
Oz (precordical processing) 20 0.007
N14 latency, ms 16.00 ± 0.97 17.35 ± 3.37 43 1.35 p = .090
P18 latency, ms 19.35 ± 1.87 19.43 ± 3.13 37 0.08 p = .98
P2P amplitude, μV 0.44 ± 0.31 0.22 ± 0.25 37 −0.22 p = .004
CP5 (early cortical processing) 20 36 0.000
N20 latency, ms 21.95 ± 1.36 24.36 ± 3.17 2.41 p = .003
P22 latency, ms 31.4 ± 3.68 37.28 ± 7.03 5.88 p = .001
P2P amplitude, μV 3.95 ± 2.21 6.45 ± 3.08 2.50 p = .002
C1 (late cortical processing) 20 46 0.004
N60 latency, ms 70.35 ± 7.43 109.43 ± 50.51 39.08 p = .001
P80 latency, ms 107.25 ± 20.98 161.80 ± 64.74 54.55 p = .000
P2P amplitude, μV 2.83 ± 1.58 2.49 ± 1.67 −0.34 p = .50
Oz-C1 (central conduction time) 20 43
N14–N60, ms 54.35 ± 7.18 94.77 ± 50.81 40.42 p = .001
Data are expressed andmean and SD unless otherwise stated. p-Values b .05 indicate significant differences One-way multivariate analysis of variance (MANOVA)with age and height as
covariates is used when comparing healthy controls and people with diabetes. Spearman and Bonferroni corrected.
Fig. 1. Graphical presentation of the evoked potentials recorded from different levels in the ascending pathway, following electrical stimulation of the median nerve. Average of all
participants with and without diabetes.
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Table 3
Assessment of correlation between central conduction time and clinically parameters.
Central conduction time and: N Healthy p-Value N Diabetes p-Value
Age 20 −0.12 0.62 43 0.03 0.83
Height 20 0.14 0.56 43 0.23 0.13
Disease duration 43 0.02 0.89
Median nerve conduction
velocity, motor threshold
20 −0.13 0.60 43 −0.35 0.023
Median nerve action potential,
motor threshold
20 0.28 0.23 43 0.07 0.68
Cardiac vagal tone 18 −0.52 0.027 32 −0.35 0.047
Correlations are assessed by Spearman's Rho and corrected by Bonferroni for multiple
comparisons. p-Values b .05 indicate significant association.
5T.D. Nissen et al. / Journal of Diabetes and Its Complications 34 (2020) 1076143.2. Associations between central conduction time and age, height, disease
duration, median nerve conduction velocity, median nerve amplitude and
parasympathetic tone
There were no significant correlations between central conduction
time and age, height, disease duration or median nerve action potential
for none of the two groups. In diabetes increased central conduction
time was correlated to decreased median nerve conduction velocity
(Table 3). Increased central conduction time was correlated to de-
creased parasympathetic tone (CVT) in both healthy and participants
with diabetes.
4. Discussion
We have demonstrated that in diabetes and confirmed DSPN, the
extensive neuronal changes are manifest as decreased conduction ve-
locities and amplitudes of action potentials at peripheral and central
levels. The neuronal transmission was prolonged as the nerve signal
travels up through the system and passes an increasing number of syn-
apses, which is reflected in the central conduction time. The findings
confirm that neuronal transmission is altered at different anatomical
levels of the upstream activation, confirming de-myelinisation, axonal
loss, altered central processing and delayed inter-neuronal communica-
tion. Finally, associations between increased central conduction time
and diminished parasympathetic tone indicate extensive neuronal
pathophysiological processes which may progress in parallel.
4.1. Diabetes induced changes at the peripheral level
Nerve conduction studies have classically been used to objectively
detect peripheral nerve dysfunctions and have the advantage to e.g.
MRI studies, that they assess the functional capacity of the largemyelin-
ated peripheral nerves, and thereby serve as a proxy for the severity of
DSPN. In the present study, DSPN was diagnosed by assessing motor
and sensory nerves of the upper and lower extremities conducted by
trained neurophysiologists and our measures of nerve transmission at
Erb's point confirmed the diagnosis. However, we did not find an asso-
ciation between median nerve conduction velocity and latencies of
SEPs. The median nerve conduction velocity from the clinical neuro-
physiological investigation is based on electrodes situated proximal to
the wrist and distal to the elbow (approximate distance 200 mm). In
contrast the conduction velocity (latency) from the evoked potentials
calculated from the stimulation point of the median nerve to the Erb's
point travel across joint near structures at the elbow and shoulder. Con-
sequently, the two measures support each other, but are not directly
comparable. It is established that in response to long-term hyperglyce-
mic exposure both myelin sheaths and the axons itself are affected by
changes to the neuronal microenvironment.19,20 Therefore, the de-
creased nerve conduction velocity and prolonged latency in the sensory
median nerve, serves as a proxy of the health of axons and myelin
sheath. Consequently, reduced conduction velocity can arise fromDownloaded for Anonymous User (n/a) at Aalborg Hospital fro
For personal use only. No other uses without permission. Cdegeneration ofmyelin sheath aswell as axonal loss or dysfunction.21,22
Concomitantly the evidence of reduced amplitudes in the evoked
potentials andmeasurements of the diminished action potential ampli-
tude in peripheral nerves is indicative of axonal atrophy.23 In conclu-
sion, these findings are in accordance with characteristic evidence in
diabetic polyneuropathy.22,24,25
4.2. Diabetes induced changes at the spinal and cerebral levels
As the signal travels up-stream through the spinal cord (Cv7), the
subcortical level (Oz), and the cortical level (CP5 and C1) an increasing
number of synapses and inter-neuronal communications are involved.
Hence, group differences at these points are considered the net effect
of changes in nerve integrity, synaptic transmission, and cortical pro-
cessing. Indeed, the prolongation of the central conduction time in dia-
betes indicates extensive alterations of the central response and it can
be speculated that the delayed synaptic transmission contributes pro-
portionally more than reduced conduction velocity to the final latencies
of SEP's. In addition, the amplitude of specific electrodes represents
central synchronicity of the firing pattern in a number of neurons the
so-called central processing of the afferent signal. Furthermore, the am-
plitudes of the SEPs at spinal, subcortical and late cortical assessment
points were consistently reduced indicating extensive axonopathy.
The stimulus intensity to evoke motoric twitch of the thumb, was
approximately 50% larger in people with diabetes and consequently
the observed decreased amplitudes may be under estimated. However,
a reduced amplitude could also be an effect of increased latency jitter26
and therefore we cannot rule out that this contributes to the reduction
in amplitudes. Interestingly, at the early cortical level the amplitude
was increased,which hypothetically could be interpreted as hyperexcit-
ability of the thalamus. In addition, the different effect onmeasured am-
plitudes at the different cerebral positions could also represent changes
in involved pathways, involved networks and integrity of the cortical
processing.27–29
Ourfindings are supported by other studies. A previous study in type
2 diabetes, also showed prolongation of latencies and reduced ampli-
tude to electrical median nerve stimulation, indicating a shared patho-
genesis of neuropathy in type 1 and type 2 diabetes.13
Nakamura et al.12 investigated neuropathy in a mixed cohort of
type 1 and 2 diabetes with an average disease duration of approxi-
mately 8 years, which supports our findings of increased latency
after median nerve stimulation Furthermore, Ziegler et al.9 con-
ducted pioneering work where neuropathy in type 1 diabetes was
thoroughly investigated and reported increased latency and reduced
amplitudes in peripheral, spinal and cortical SEP's following tibial
nerve stimulation. However, in contrast to the present study previ-
ously studies have not reported alterations in central conduction
time.9,13 Taken together, these studies conclude consistently that
the conduction abnormalities in diabetes involves central as well as
peripheral somatosensory pathways.13 Therefore, our study expands
the generalizability of their findings, to also include people with long
term (32 years) type 1 diabetes, who have received stable hypergly-
cemic medication including fast and long acting insulin with dosing
adjustment according to contemporary regimens, minimizing hypo
and hyperglycemic induced neurotoxicity.
Central and peripheral changes of the diabetic neuropathy have
been shown by use of different neurophysiological and imaging
techniques.30–32 Studies on resting state EEG have shown altered spon-
taneous brain oscillations and cortical processing10 and other EEG stud-
ies in peoplewith diabetes have shown altered cerebral processingwith
functional reorganization.27–29 EEG changes has previously been ob-
served in people with type 1 diabetes and visceral neuropathy, which
steadily have shown increased latency and decreased amplitude of
sensory evoked brain potentials following electrical esophageal
stimulation.5 Consequently, these studies support the present findings.
In addition, in people with diabetes and upper gastrointestinalm ClinicalKey.com by Elsevier on September 09, 2020.
opyright ©2020. Elsevier Inc. All rights reserved.
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were involved in symptom generation andmaintenance.4 Furthermore,
the involved brain networks encoding the visceral sensation was
altered.28 Finally, in support of ourfindingswhich emphasizes extensive
multilevel neuronal damage, a study showed association between
peripheral nerve conduction deficiencies and acquired cognitive
impairment.34
4.3. Associations between central conduction time and parasympathetic
tone
The study showed an association between prolonged central con-
duction time and diminished parasympathetic tone, indicating that
the pathophysiology leading to neuropathymay be shared in autonomic
and central neuropathies. Cardiac vagal tone represents themodulatory
efferent vagal nerve originating from the brainstem and influencing the
heart. The concomitant presence of abnormal response in the brain and
brainstem may represent shared pathophysiological genesis, however
since the data is cross sectional it does not allow for a causative interpre-
tation. The association was present in both controls and people with di-
abetes, indicating that CVTmay serve as a proxy of the general integrity
of the nervous system, and not only when extensive neuronal alter-
ations are present.
4.4. Methodological considerations and limitations
Firstly, glycemic variability is a risk factor for diabetic
polyneuropathy35 and hypo- and hyperglycemic exposure are known
to beneurotoxic.36 Studies have shown that long-termoptimal glycemic
control in type 1 diabetes was associated with near-normal nerve
function.37,38
In the present study, recording of the number of hyper- and hypo-
glycemic was limited to the preceding 48 h and glycemic control was
onlymeasured byHbA1C, reflecting precedingmonth's glycemic fluctu-
ations and therefore future studies will be improved by assessing con-
tinuous glucose monitoring. Secondly, as blood glucose directly
influences the neuronal function, it cannot be ruled out that the
normoglycemia in participants without diabetes will overestimate the
impact of hyperglycemia on nerve function, as the difference in glucose
level could have affected not only the nerve conduction – but also the
processing in the brain – however results are ambiguous.39,40 Thirdly,
median nerve conduction velocity is only part of the Toronto criteria
used to verify DSPN. The clinical diagnose is based on measurements
from sensory and motor nerves from upper and lower extremities,
and consequently recordings from themedian nerve does not necessar-
ily have to be abnormal in these patients even though they were diag-
nosed with DSPN. From the demographics it is evident, that extensive
neuronal changes were present in diabetes.
However, a composite severity score as suggested by Dyck et al.,41,42
may have been used to assess the severity of neuropathy. Such score has
previously shown association to severity of peripheral and central neu-
ronal changes.9 Fourthly, a comparative group of matched participants
with type 1 diabetes but without DSPN or a group of people with the
presence of neuropathy for other reasons than diabetes, would have
strengthened the study and the present findings do not allow to con-
cludewhether the results of this study are due to peripheral neuropathy
alone or neuropathy caused by diabetes. Fifthly, the presence of carpal
tunnel syndrome is higher in diabetes and is known to affect nerve
transmission passing the carpus. However, to limit this influence the
present nerve conduction velocity of the median nerve was assessed
fromwrist to elbow, minimizing this effect. Finally, themajority of peo-
ple with diabetes are pre-disposed to co-morbidities andmay therefore
receive other medication. However, medication which could influence
nerve-function was part of the exclusion criteria. Interestingly, our
data show that people with diabetes are in tight control of hypercholes-
terolemia (statins) in accordance with treatment guidelines andDownloaded for Anonymous User (n/a) at Aalborg Hospital 
For personal use only. No other uses without permissioconsequently had lower levels of cholesterol, which are reflected in
their reference values range. (normal value: healthy b5.0; diabetics
b4.0).5. Conclusion
This study provides evidence of changes in the ascending sensory
pathway from the periphery and spinal cord to the cortical response
in long term type 1 diabetes mellitus and confirmed DSPN. Extensive
neuronal impairment manifest as decreased conduction velocities,
decreased amplitudes, decreased central conduction time indicate
impaired inter-neuronal communication. Furthermore, decreased para-
sympathetic tone was associated with prolonged central conduction
time. These findings confirm that diabetes induces neuronal impair-
ment at multiple anatomical levels– involving peripheral, autonomic
and central nerves.Funding
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